<document>

<filing_date>
2020-03-05
</filing_date>

<publication_date>
2020-09-17
</publication_date>

<priority_date>
2019-03-08
</priority_date>

<ipc_classes>
A61K9/00,A61K9/08,A61K9/19,C07K16/28
</ipc_classes>

<assignee>
BOEHRINGER INGELHEIM INTERNATIONAL
</assignee>

<inventors>
STEINER, Anna Maria
SINGH, Ravija
WRIGHT, Sara Kay
MEHRA, Rajni Prasad
PRESSER, Ingo Michael
KATAYAMA, Derrick Spencer
DENKINGER, Sandra Nicole
</inventors>

<docdb_family_id>
70009446
</docdb_family_id>

<title>
ANTI-IL-36R ANTIBODY FORMULATIONS
</title>

<abstract>
The present invention relates to anti-IL-36R formulations for administration to a subject.
</abstract>

<claims>
1. A pharmaceutical formulation comprising:
a. An anti-IL-36R antibody or an antigen binding fragment thereof
present at a concentration within the range from about 0.5 mg/mL to about 220 mg/mL;
b. A buffer present at a concentration within the range from about 20 mM to about 80 mM;
c. A tonicifying agent present at a concentration within the range from about 100 mM to about 250 mM;
wherein the formulation is characterized by a pH within the range from about 5 to about 8 when in aqueous form.
2. The pharmaceutical formulation of claim 1 , wherein the formulation is in liquid or powder form.
3. The pharmaceutical formulation of claim 1 or 2, wherein the anti-IL-36R antibody is present at a concentration of within the range from about 10 mg/mL to about 200 mg/mL.
4. The pharmaceutical formulation of claim 1 , wherein the anti-IL-36R
antibody is present at a concentration of about 20 mg/mL.
5. The pharmaceutical formulation of claim 1 , wherein the anti-IL-36R
antibody is present at a concentration of about 60 mg/mL.
6. The pharmaceutical formulation of claim 1 , wherein the anti-IL-36R
antibody is present at a concentration of about 150 mg/mL.
7. The pharmaceutical formulation of any one of claims 1 to 6, wherein the buffer comprises histidine, phosphate, succinate, citrate, acetate or TRIS.
8. The pharmaceutical formulation of claim 7, wherein the buffer comprises citrate or acetate.
9. The pharmaceutical formulation of claim 7, wherein the buffer comprises histidine.
10. The pharmaceutical formulation of claim 8, wherein the buffer comprises acetate.
1 1 . The pharmaceutical formulation of any one of claims 1 to 10, wherein the tonicifying agent is one or more sugar and/or polyol.
12. The pharmaceutical formulation of claim 1 1 , wherein the tonicifying agent is one or more sugar and/or polyol comprising sucrose, trehalose, sorbitol, glycerol, mannitol or dextrose.
13. The pharmaceutical formulation of claim 12, wherein the tonicifying agent comprises sucrose or trehalose.
14. The pharmaceutical formulation of claim 13, wherein the tonicifying agent comprises sucrose.
15. The pharmaceutical formulation of claim 13, wherein the tonicifying agent comprises trehalose.
16. The pharmaceutical formulation of any one of claims 1 to 15, wherein the formulation further comprises a stabilizer present at a concentration within the range from about 0 mM to about 80 mM.
17. The pharmaceutical formulation of claim 16, wherein the stabilizer
comprises an amino acid comprising arginine, histidine, glycine, cysteine, proline, methionine, lysine, aspartate, glutamate or pharmaceutically acceptable salts thereof.
18. The pharmaceutical formulation of claim 16, wherein the stabilizer
comprises L-arginine or pharmaceutically acceptable salts thereof.
19. The pharmaceutical formulation of any one of claims 1 1 -15, wherein the formulation further comprises a salt present at a concentration of within the range from about 0 to about 150 mM.
20. The pharmaceutical formulation of claim 19, wherein the salt comprises sodium chloride (NaCI), magnesium chloride (MgCl2), magnesium sulfate (MgSC ), potassium chloride (KCI), lithium chloride (LiCI), calcium chloride (CaCl2), boric acid salts or zinc chloride (ZnCl2).
21 . The pharmaceutical formulation of claim 19, wherein the salt comprises sodium chloride (NaCI).
22. The pharmaceutical formulation of claim 1 , wherein the formulation further comprises a surfactant present at a concentration within the range from about 0.1 g/L to about 1 .5 g/L.
23. The pharmaceutical formulation of claim 22, wherein the surfactant
comprises poloxamer 188, polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80.
24. The pharmaceutical formulation of claim 22, wherein the surfactant
comprises polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80.
25. The pharmaceutical formulation of claim 22, wherein the surfactant comprises polysorbate 20.
26. The pharmaceutical formulation of claim 22, wherein the surfactant comprises polysorbate 80.
27. A pharmaceutical formulation comprising: a. an anti-IL-36R antibody or an antigen binding fragment thereof present at a concentration within the range from about 10 mg/mL to about 200 mg/mL; b. acetate and / or histidine buffer present at a concentration within the range from about 20 mM to about 80 mM; c. sucrose and / or trehalose present at a concentration within the range from about 100 mM to about 250 mM; d. L-arginine and / or pharmaceutically acceptable salts thereof present at a concentration within the range from about 0 mM to about 80 mM; e. sodium chloride (NaCI) present at a concentration of within the range from about 0 to about 150 mM; and f. polysorbate 20 and/or polysorbate 80 present at a concentration within the range from about 0 g/L to about 1 .5 g/L; wherein the formulation is characterized by a pH within the range from about 5 to about 7 when in aqueous form.
28. A pharmaceutical formulation comprising: a. an anti-IL-36R antibody or an antigen binding fragment thereof present at a concentration of about 20 mg/mL; b. an citrate buffer present at a concentration at a concentration of about 25 mM; c. sucrose and / or trehalose present at a concentration of about 200 mM; d. polysorbate 80 present at a concentration of about 0.4 g/L; wherein the formulation is characterized by a pH within the range from about 6 to about 7 when in aqueous form.
29. A pharmaceutical formulation comprising: a. an anti-IL-36R antibody or an antigen binding fragment thereof present at a concentration of about 60 mg/mL;
b. an acetate buffer present at a concentration of about 45 mM;
c. sucrose and / or trehalose present at a concentration of about 150 mM;
d. L-arginine or pharmaceutically acceptable salts thereof present at a concentration of about 25 mM; and e. polysorbate 20 present at a concentration of about 0.4 g/L; wherein the formulation is characterized by a pH within the range from about 5 to about 6 when in aqueous form.
30. A pharmaceutical formulation comprising: a. an anti-IL-36R antibody or an antigen binding fragment thereof present at a concentration of about 150 mg/mL;
b. an acetate buffer present at a concentration at a concentration of about 45 mM;
c. sucrose or trehalose present at a concentration of about 150 mM; d. L-arginine or pharmaceutically acceptable salts thereof present at a concentration of about 25 mM; and
e. polysorbate 20 present at a concentration of about 0.4 g/L; wherein the formulation is characterized by a pH within the range from about 5 to about 6 when in aqueous form.
31 . The pharmaceutical formulation of any one of claims 1 -30, wherein the formulation is characterized by an osmolality within the range from about 210 mOsmol/kg to about 390 mOsm/kg.
32. The pharmaceutical formulation of any one of claims 1 -31 , wherein less than about 5% of the antibody is present in an aggregate form in the formulation.
33. The pharmaceutical formulation of any one of claims 1 -32, wherein the formulation is sterile.
34. The pharmaceutical formulation of any one of claims 1 -33, wherein the formulation is stable upon freezing and thawing.
35. The pharmaceutical formulation of any of claims 1 -34, wherein the formulation comprises water or is reconstituted with water.
36. The pharmaceutical formulation of any of claims 1 -35, wherein the formulation has a pH of between about 5 to about 6 in liquid form or when reconstituted with water.
37. The pharmaceutical formulation of any of claims 1 -36, wherein the formulation has a pH of about 6 in liquid or when reconstituted with water.
38. The pharmaceutical formulation of any of claims 1 -37, wherein the formulation has at least one feature selected from the group consisting of:
(i) Increased shelf life
(ii) better temperature stability,
(iii) decreased formation of aggregates,
(iv) better chemical stability,
(v) decreased viscosity, and
as compared to a reference formulation.
39. The pharmaceutical formulation of any of claims 1 -37, wherein the formulation having at least one feature selected from the group consisting of:
(a) decreased percentage of aggregates as measured by High Performance Size Exclusion Chromatography (HP-SEC),
(b) higher percentage of monomers as measured by HPSEC,
(c) higher percentage of main peak (less degradation of charge variants) measured by CEX,
(d) lower percentage of subvisible particles such as > 10 pm and > 25 pm, and
(e) lower turbidity value in Formazine Nephelometry Units (FNU),
after storage at about 40Â°C as compared to the reference formulation.
40. A pharmaceutical product comprising a vial or syringe comprising the pharmaceutical formulation according to any of claims 1 to 39.
41 . A pharmaceutical product according to claim 40 further comprising a pre assembled injection device.
42. The pharmaceutical product of claim 41 , wherein the pre-assembled
injection device is an autoinjector or needle safety device.
43. A pre-assembled injection device comprising a pharmaceutical formulation according to any one of claims 1 to 39.
44. The pre-assembled injection device according to claim 43, wherein said device is an autoinjector or needle safety device or a syringe.
45. The pre-assembled injection device according to claim 43, wherein said formulation is suitable for subcutaneous administration or intramuscular administration.
46. A kit of parts, comprising at least a container comprising a pharmaceutical formulation according to any one of claims 1 -39, and an injection device.
47. The kit of claim 46, comprising an instruction for subcutaneous or
intramuscular administration of the formulation to a subject or an instruction for subcutaneous or intramuscular self-administration.
48. The pharmaceutical formulation of any of claim 1 -39, wherein the anti-IL- 36R antibody or antigen-binding fragment thereof comprises: a. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 35, 102, 103, 104, 105 106 or 140 (L-CDR2); the amino acid sequence of SEQ ID NO: 44 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 62, 108, 109, 1 10 or 1 1 1 (HCDR2); the amino acid sequence of SEQ ID NO: 72 (H-CDR3); or b. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26 (L-CDR1 ); the amino acid sequence of SEQ ID NO:
102 (L-CDR2); the amino acid sequence of SEQ ID NO: 44 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 62, 108, 109, 1 10 or 1 1 1 (H-CDR2); the amino acid sequence of SEQ ID NO: 72 (H-CDR3); or c. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26 (L-CDR1 ); the amino acid sequence of SEQ ID NO:
103 (L-CDR2); the amino acid sequence of SEQ ID NO: 44 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 62, 108, 109, 1 10 or 1 1 1 (H-CDR2); the amino acid sequence of SEQ ID NO: 72 (H-CDR3); or d. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26 (L-CDR1 ); the amino acid sequence of SEQ ID NO:
104 (L-CDR2); the amino acid sequence of SEQ ID NO: 44 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 62, 108, 109, 1 10 or 1 1 1 (H-CDR2); the amino acid sequence of SEQ ID NO: 72 (H-CDR3); or e. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26 (L-CDR1 ); the amino acid sequence of SEQ ID NO:
105 (L-CDR2); the amino acid sequence of SEQ ID NO: 44 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 62, 108, 109, 1 10 or 1 1 1 (H-CDR2); the amino acid sequence of SEQ ID NO: 72 (H-CDR3); or f. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26 (L-CDR1 ); the amino acid sequence of SEQ ID NO:
106 (L-CDR2); the amino acid sequence of SEQ ID NO: 44 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 62, 108, 109, 1 10 or 1 1 1 (H-CDR2); the amino acid sequence of SEQ ID NO: 72 (H-CDR3); or g. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26 (L-CDR1 ); the amino acid sequence of SEQ ID NO:
140 (L-CDR2); the amino acid sequence of SEQ ID NO: 44 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 62, 108, 109, 1 10 or 1 1 1 (H-CDR2); the amino acid sequence of SEQ ID NO: 72 (H-CDR3).
49. The pharmaceutical formulation of any of claims 1 -39, wherein the
antibody or antigen binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of any one of SEQ ID NO: 76, 77, 78, 79, 80, 81 , 82 or 83; and a heavy chain variable region comprising the amino acid sequence of any one of SEQ ID NO: 87, 88, 89, 90, 91 , 92, 93, 94 or 95.
50. The pharmaceutical formulation of any of claims 1 -39, wherein the anti-IL- 36R antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising the amino acid sequence of SEQ ID NO: 77; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87;or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 77; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 88; or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 77; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 89; or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 80; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87;or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 80; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 88; or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 80; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 89.
51 . The pharmaceutical formulation of any of claims 1 -39, wherein the anti-IL- 36R antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of any one of SEQ ID NO: 84, 85 or 86; and a heavy chain variable region comprising the amino acid sequence of any one of SEQ ID NO: 96, 97, 98, 99, 100 or 101 .
52. The pharmaceutical formulation of any of claims 1 -39, wherein the anti-IL- 36R antibody or antigen-binding fragment thereof comprises:
a light chain variable region comprising the amino acid sequence of SEQ ID NO: 85; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 100; or
a light chain variable region comprising the amino acid sequence of SEQ ID NO: 85; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:101 ; or
a light chain variable region comprising the amino acid sequence of SEQ ID NO: 86; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 100; or
a light chain variable region comprising the amino acid sequence of SEQ ID NO: 86; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:101 .
53. The pharmaceutical formulation of any of claims 1 -39, wherein the anti-IL- 36R antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence of any one of SEQ ID NO: 1 14, 1 15, 1 16, 1 17, 1 18, 1 19, 120 or 121 ; and a heavy chain comprising the amino acid sequence of any one of SEQ ID NO: 125, 126, 127, 128, 129, 130, 131 , 132 or 133.
54. The pharmaceutical formulation of any of claims 1 -39, wherein the anti-IL- 36R antibody or antigen-binding fragment thereof comprises:
a light chain comprising the amino acid sequence of SEQ ID NO: 1 15; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 125; a light chain comprising the amino acid sequence of SEQ ID NO: 1 15; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 126; a light chain comprising the amino acid sequence of SEQ ID NO: 1 15; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 127; a light chain comprising the amino acid sequence of SEQ ID NO: 1 18; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 125; a light chain comprising the amino acid sequence of SEQ ID NO: 1 18; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 126; or a light chain comprising the amino acid sequence of SEQ ID NO: 1 18; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 127.
55. The pharmaceutical formulation of any of claims 1 -39, wherein the anti-IL- 36R antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence of any one of SEQ ID NO: 122, 123 or 124; and a heavy chain comprising the amino acid sequence of any one of SEQ ID NO: 134, 135, 136, 137, 138 or 139.
56. The pharmaceutical formulation of any of claims 1 -39, wherein the anti-IL- 36R antibody or antigen-binding fragment thereof comprises:
a light chain comprising the amino acid sequence of SEQ ID NO: 123; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 138; a light chain comprising the amino acid sequence of SEQ ID NO: 123; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 139; or a light chain comprising the amino acid sequence of SEQ ID NO: 124; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 138.
57. The pharmaceutical formulation of any of claims 1 -39, wherein the anti-IL- 36R antibody or antigen-binding fragment thereof comprises: a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 103 (L-CDR2); the amino acid sequence of SEQ ID NO: 44 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 62 (HCDR2); the amino acid sequence of SEQ ID NO: 72 (H-CDR3); b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 104 (L-CDR2); the amino acid sequence of SEQ ID NO: 44 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 62 (HCDR2); the amino acid sequence of SEQ ID NO: 72 (H-CDR3); c) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 27 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 36 (LCDR2); the amino acid sequence of SEQ ID NO: 45 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 107 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 63 (HCDR2); the amino acid sequence of SEQ ID NO: 73 (H-CDR3); or d) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 27 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 36(LCDR2); the amino acid sequence of SEQ ID NO: 45 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 107 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 64 (HCDR2); the amino acid sequence of SEQ ID NO: 73 (H-CDR3).
58. The pharmaceutical formulation of any of claims 1 -39, wherein the anti-IL- 36R antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising the amino acid sequence of SEQ ID NO: 21 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 30 (LCDR2); the amino acid sequence of SEQ ID NO: 39 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 48 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 57 (HCDR2); the amino acid sequence of SEQ ID NO: 67 (H-CDR3); or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 31 (LCDR2); the amino acid sequence of SEQ ID NO: 40 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 49 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 58 (HCDR2); the amino acid sequence of SEQ ID NO: 68 (H-CDR3); or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 23 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 32 (LCDR2); the amino acid sequence of SEQ ID NO: 41 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 50 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 59 (HCDR2); the amino acid sequence of SEQ ID NO: 69 (H-CDR3); or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 24 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 33 (LCDR2); the amino acid sequence of SEQ ID NO: 42 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 51 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 60 (HCDR2); the amino acid sequence of SEQ ID NO: 70 (H-CDR3); or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 25 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 34 (LCDR2); the amino acid sequence of SEQ ID NO: 43 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 61 (HCDR2); the amino acid sequence of SEQ ID NO: 71 (H-CDR3); or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 35 (LCDR2); the amino acid sequence of SEQ ID NO: 44 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 62 (HCDR2); the amino acid sequence of SEQ ID NO: 72 (H-CDR3); or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 27 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 36 (LCDR2); the amino acid sequence of SEQ ID NO: 45 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 63 (HCDR2); the amino acid sequence of SEQ ID NO: 73 (H-CDR3); or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 27 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 36 (LCDR2); the amino acid sequence of SEQ ID NO: 45 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 64 (HCDR2); the amino acid sequence of SEQ ID NO: 73 (H-CDR3); or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 28 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 37 (LCDR2); the amino acid sequence of SEQ ID NO: 46 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 55 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 65 (HCDR2); the amino acid sequence of SEQ ID NO: 74 (H-CDR3); or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 29 (L-CDR1 ); the amino acid sequence of SEQ ID NO: 38 (LCDR2); the amino acid sequence of SEQ ID NO: 47 (L-CDR3); and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56 (H-CDR1 ); the amino acid sequence of SEQ ID NO: 66 (HCDR2); the amino acid sequence of SEQ ID NO: 75 (H-CDR3).
59. A pharmaceutical formulation comprising: a. an anti-IL-36R antibody or antigen-binding fragment thereof
comprising: a light chain comprising an amino acid sequence set forth as SEQ ID NO:1 18 and a heavy chain comprising an amino acid sequence set forth as SEQ ID NO:125; or ii. a light chain comprising an amino acid sequence set forth as SEQ ID NO:1 18 and a heavy chain comprising an amino acid sequence set forth as SEQ ID NO:126; or iii. a light chain comprising an amino acid sequence set forth as SEQ ID NO:1 18 and a heavy chain comprising an amino acid sequence set forth as SEQ ID NO:127; wherein the antibody is present at a concentration of about 20 mg/ml_, 60 mg/ml_ or 150 mg/mL; and b. acetate buffer present at a concentration of about 45 mM; c. sucrose present at a concentration of about 150 mM; d. L-arginine HCI present at a concentration of about 25 mM; e. polysorbate 20 present at a concentration of about 0.4 g/L; and wherein the formulation is characterized by a pH within the range from about 5 to about 6.
60. A powder pharmaceutical formulation wherein when reconstituted
with water yields an aqueous solution comprising: a. an anti-IL-36R antibody or antigen-binding fragment thereof
comprising: i. a light chain comprising an amino acid sequence set
forth as SEQ ID NO:1 18 and a heavy chain comprising an amino acid sequence set forth as SEQ ID NO:125; or ii. a light chain comprising an amino acid sequence set
forth as SEQ ID NO:1 18 and a heavy chain comprising an amino acid sequence set forth as SEQ ID NO:126; or iii. a light chain comprising an amino acid sequence set
forth as SEQ ID NO:1 18 and a heavy chain comprising an amino acid sequence set forth as SEQ ID NO:127; and b. histidine buffer present at a concentration of about 25 mM; c. sucrose and/or mannitiol present at a concentration of about 180 mM; d. polysorbate 20 present at a concentration of about 0.2 g/L; and wherein the formulation is characterized by a pH within the range from about 5 to about 7 when reconstituted with water.
61 . The powder formulation of claim 60, wherein the antibody is
present at a concentration of about 20 mg/mL, 60 mg/mL or 150 mg/ml_.
62. The powder formulation of claim 60, wherein the formulation
comprises about 100 mg to about 1500 mg of the antibody and is reconstitutable with water for injection.
63. A method of making a pharmaceutical formulation comprising: a. culturing mammalian cells having stably incorporated into their genome one or more nucleic acids encoding the light and heavy chains of an anti-IL-36R antibody so that the cells secrete the antibody into the cell culture media, and purifying the antibody from the cell culture media; and b. preparing the formulation according to any of claims 1 -39.
64. The method of claim 63, wherein the nucleic acid encoding the
light of the anti-IL-36R antibody comprises a nucleotide sequence encoding SEQ ID NO:1 18, and wherein the nucleic acid encoding the heavy chain of the anti-IL-36R antibody comprises a nucleotide sequence encoding SEQ ID NO:125.
65. The method of claim 63, wherein the nucleic acid encoding the
light of the anti-IL-36R antibody comprises a nucleotide sequence encoding SEQ ID NO:1 18, and wherein the nucleic acid encoding the heavy chain of the anti-IL-36R antibody comprises a nucleotide sequence encoding SEQ ID NO:126.
66. The method of claim 63, wherein the nucleic acid encoding the
light of the anti-IL-36R antibody comprises a nucleotide sequence encoding SEQ ID NO:1 18, and wherein the nucleic acid encoding the heavy chain of the anti-IL-36R antibody comprises a nucleotide sequence encoding SEQ ID NO:127.
67. A pharmaceutical product, comprising: a vial comprising about
100 mg to 1500 mg an anti-IL-36R antibody in powder form;
instructions for reconstitution of the anti-IL-36R antibody; and instructions for preparing the reconstituted antibody for infusion, wherein the anti-IL-36R antibody comprises a light chain
comprising an amino acid sequence set forth as SEQ ID NO:1 18 and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID Nos:125, 126 or 127; and the reconstitution instructions require reconstitution with water for injection to an extractable volume from 1 to 50 ml_.
68. The pharmaceutical formulation of claim 7, wherein the buffer comprises citrate.
69. A pharmaceutical formulation comprising:
a. An anti-IL-36R antibody or an antigen binding fragment thereof
present at a concentration within the range from about 0.5 mg/mL to about 220 mg/mL;
b. A buffer present at a concentration within the range from about 20 mM to about 80 mM;
c. A tonicifying agent present at a concentration within the range from about 100 mM to about 400 mM;
wherein the formulation is characterized by a pH within the range from about 5 to about 8 when in aqueous form.
</claims>
</document>
